ADARx Pharmaceuticals (ADRX) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.57B and a free-cash-flow yield of 24.3%. Nama's AI scorecard rates it Hold, 5.5 out of 10.
AI scorecard
Hold · 5.5/10
The sections balance. As of Nov 20, 2026.
Shariah screen
Not Shariah Compliant
At least one of the three ratios or the industry test failed.
Off its high
-44.9%
How far the last close sits under the highest price of the past five years.
Market cap
$1.57B
Trailing P/E
—
Price / book
—
Price / sales
236.0
FCF yield
24.3%
Dividend yield
—
Gross margin
0.0%
Operating margin
-1735.0%
Net margin
0.0%
Revenue growth (YoY)
—
Revenue growth (3-yr annual)
—
EPS growth (YoY)
—
FCF/share growth (YoY)
—
Beta
—
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
ADRX earnings
Next report: Feb 18, 2027 (Q4 2026, EPS estimate -$0.37).
Beat the EPS estimate in 0 of 1 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q3 2026
Nov 12, 2026
-$1.74
-$0.73
-138.4%
$2.22M
ADRX analyst price target
Median target $33.50 from 4 analysts, ranging $32.00 – $36.00.
Nama's AI scorecard currently rates ADARx Pharmaceuticals Hold (5.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does ADRX report earnings?
ADARx Pharmaceuticals's next scheduled report is on Feb 18, 2027. Analysts expect EPS of -$0.37.
What is the ADRX price target?
The median analyst price target from 4 analysts is $33.50, with a range of $32.00 – $36.00.
Is ADRX Shariah compliant?
Nama's AAOIFI-style screen reads ADARx Pharmaceuticals as Not Shariah Compliant. At least one of the three ratios or the industry test failed.